Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide

References

• Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998;53:127–40
   PubMedGoogle Scholar
• Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109–16
   PubMedGoogle Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–59
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991;1:213–16
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Morphological changes in the human cerebral cortex in dementia. J Hirnforsch 1991;32:277–82
   PubMedGoogle Scholar
• Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095–7
   PubMed Web of Science ®Google Scholar
• Alafuzoff I, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S, Bodi I, Boluda S, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:309–20
   PubMed Web of Science ®Google Scholar
• Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 1987;57:230–6
   PubMed Web of Science ®Google Scholar
• Hamazaki H. Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem Biophys Res Commun 1995;211:349–53
   PubMed Web of Science ®Google Scholar
• Klunk WE, Pettegrew JW. Alzheimer's beta-amyloid protein is covalently modified when dissolved in formic acid. J Neurochem 1990;54:2050–6
   PubMed Web of Science ®Google Scholar
• Klunk WE, Xu CJ, Pettegrew JW. NMR identification of the formic acid-modified residue in Alzheimer's amyloid protein. J Neurochem 1994;62:349–54
   PubMed Web of Science ®Google Scholar
• Ma J, Yee A, Brewer HB Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994;372:92–4
   PubMed Web of Science ®Google Scholar
• Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem 1995;270:7563–7
   PubMed Web of Science ®Google Scholar
• Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996;316:671–9
   PubMed Web of Science ®Google Scholar
• Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 1995;136:22–31
   PubMed Web of Science ®Google Scholar
• Orlando R, Kenny PT, Zagorski MG. Covalent modification of Alzheimer's amyloid beta-peptide in formic acid solutions. Biochem Biophys Res Commun 1992;184:686–91
   PubMed Web of Science ®Google Scholar
• Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid 1997;4:274–95
   Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–81
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098–102
   PubMed Web of Science ®Google Scholar
• Veerhuis R, Boshuizen RS, Familian A. Amyloid associated proteins in Alzheimer's and prion disease. Curr Drug Targets CNS Neurol Disord 2005;4:235–48
   PubMedGoogle Scholar
• Vanderstichele H, De MG, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, et al. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650–60
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452–5
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatr 1982;139:1136–9
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K. Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol 1990;79:569–72
   PubMed Web of Science ®Google Scholar
• Kennett RH, McKeam TJ, Bechtol KB. Monoclonal antibodies. Hybridomas: a new dimension in biological analysis. New York: Plenum Press; 1980
   Google Scholar
• Korth C, Streit P, Oesch B. Monoclonal antibodies specific for the native, disease-associated isoform of the prion protein. Methods Enzymol 1999;309:106–22
   PubMed Web of Science ®Google Scholar
• Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P, et al. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 2003;105:135–44
   PubMed Web of Science ®Google Scholar
• Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del TK, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002;61:282–93
   PubMed Web of Science ®Google Scholar
• Coria F, Castano EM, Frangione B. Brain amyloid in normal aging and cerebral amyloid angiopathy is antigenically related to Alzheimer's disease beta-protein. Am J Pathol 1987;129:422–8
   PubMed Web of Science ®Google Scholar
• Rozemuller AJ, van Gool WA, Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr Drug Targets CNS Neurol Disord 2005;4:223–33
   PubMedGoogle Scholar
• Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996;6:179–95
   PubMed Web of Science ®Google Scholar
• Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology 1975;25:120–6
   PubMed Web of Science ®Google Scholar
• Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 2009;48:1870–7
   PubMed Web of Science ®Google Scholar